MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors
In the aorta, diabetes activates an osteogenic program that includes expression of bone morphogenetic protein-2 (BMP2) and the osteoblast homeoprotein Msx2. To evaluate BMP2-Msx2 signaling in vascular calcification, we studied primary aortic myofibroblasts. These cells express vascular smooth muscle cell (VSMC) markers, respond to BMP2 by up-regulating Msx2, and undergo osteogenic differentiation with BMP2 treatment or transduction with a virus encoding Msx2. The osteoblast factor osterix (Osx) is up-regulated 10-fold by Msx2, but Runx2 mRNA is unchanged; the early osteoblast marker alkaline phosphatase increases 50-fold with mineralized nodule formation enhanced 30-fold. Adipocyte markers are concomitantly suppressed. To better understand Msx2 actions on osteogenesis versus adipogenesis, mechanistic studies were extended to C3H10T1/2 mesenchymal cells. Msx2 enhances osteogenic differentiation in synergy with BMP2. Osteogenic actions depend upon intrinsic Msx2 DNA binding; the gain-of-function variant Msx2(P148H) directs enhanced mineralization, whereas the binding-deficient variant Msx2(T147A) is inactive. Adipogenesis (lipid accumulation, Pparg expression) is inhibited by Msx2. By contrast, suppression of adipogenesis does not require Msx2 DNA binding; inhibition occurs in part via protein-protein interactions with C/EBPalpha that control Pparg transcription. Thus, Msx2 regulates osteogenic versus adipogenic differentiation of aortic myofibroblasts. Myofibroblasts capable of both fates can be diverted to the osteogenic lineage by BMP2-Msx2 signaling and contribute to vascular calcification.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2003 |
---|---|
Erschienen: |
2003 |
Enthalten in: |
Zur Gesamtaufnahme - volume:278 |
---|---|
Enthalten in: |
The Journal of biological chemistry - 278(2003), 46 vom: 14. Nov., Seite 45969-77 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Cheng, Su-Li [VerfasserIn] |
---|
Anmerkungen: |
Date Completed 24.12.2003 Date Revised 18.03.2022 published: Print-Electronic Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM126772894 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM126772894 | ||
003 | DE-627 | ||
005 | 20231222212559.0 | ||
007 | tu | ||
008 | 231222s2003 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n0423.xml |
035 | |a (DE-627)NLM126772894 | ||
035 | |a (NLM)12925529 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Cheng, Su-Li |e verfasserin |4 aut | |
245 | 1 | 0 | |a MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors |
264 | 1 | |c 2003 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 24.12.2003 | ||
500 | |a Date Revised 18.03.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a In the aorta, diabetes activates an osteogenic program that includes expression of bone morphogenetic protein-2 (BMP2) and the osteoblast homeoprotein Msx2. To evaluate BMP2-Msx2 signaling in vascular calcification, we studied primary aortic myofibroblasts. These cells express vascular smooth muscle cell (VSMC) markers, respond to BMP2 by up-regulating Msx2, and undergo osteogenic differentiation with BMP2 treatment or transduction with a virus encoding Msx2. The osteoblast factor osterix (Osx) is up-regulated 10-fold by Msx2, but Runx2 mRNA is unchanged; the early osteoblast marker alkaline phosphatase increases 50-fold with mineralized nodule formation enhanced 30-fold. Adipocyte markers are concomitantly suppressed. To better understand Msx2 actions on osteogenesis versus adipogenesis, mechanistic studies were extended to C3H10T1/2 mesenchymal cells. Msx2 enhances osteogenic differentiation in synergy with BMP2. Osteogenic actions depend upon intrinsic Msx2 DNA binding; the gain-of-function variant Msx2(P148H) directs enhanced mineralization, whereas the binding-deficient variant Msx2(T147A) is inactive. Adipogenesis (lipid accumulation, Pparg expression) is inhibited by Msx2. By contrast, suppression of adipogenesis does not require Msx2 DNA binding; inhibition occurs in part via protein-protein interactions with C/EBPalpha that control Pparg transcription. Thus, Msx2 regulates osteogenic versus adipogenic differentiation of aortic myofibroblasts. Myofibroblasts capable of both fates can be diverted to the osteogenic lineage by BMP2-Msx2 signaling and contribute to vascular calcification | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
650 | 7 | |a DNA-Binding Proteins |2 NLM | |
650 | 7 | |a Homeodomain Proteins |2 NLM | |
650 | 7 | |a MSX2 protein |2 NLM | |
650 | 7 | |a RNA, Messenger |2 NLM | |
650 | 7 | |a Receptors, Cytoplasmic and Nuclear |2 NLM | |
650 | 7 | |a Transcription Factors |2 NLM | |
650 | 7 | |a DNA |2 NLM | |
650 | 7 | |a 9007-49-2 |2 NLM | |
650 | 7 | |a Luciferases |2 NLM | |
650 | 7 | |a EC 1.13.12.- |2 NLM | |
650 | 7 | |a Alkaline Phosphatase |2 NLM | |
650 | 7 | |a EC 3.1.3.1 |2 NLM | |
700 | 1 | |a Shao, Jian-Su |e verfasserin |4 aut | |
700 | 1 | |a Charlton-Kachigian, Nichole |e verfasserin |4 aut | |
700 | 1 | |a Loewy, Arleen P |e verfasserin |4 aut | |
700 | 1 | |a Towler, Dwight A |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The Journal of biological chemistry |d 1945 |g 278(2003), 46 vom: 14. Nov., Seite 45969-77 |w (DE-627)NLM000004995 |x 1083-351X |7 nnns |
773 | 1 | 8 | |g volume:278 |g year:2003 |g number:46 |g day:14 |g month:11 |g pages:45969-77 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 278 |j 2003 |e 46 |b 14 |c 11 |h 45969-77 |